A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Brain Neoplasms
  • Glioblastoma
  • Neoplasm Recurrence, Local

abstract

  • This drug combination was reasonably safe, but with little indication of improvement compared to temozolomide alone.

publication date

  • February 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s11060-006-9225-y

PubMed ID

  • 17031561

Additional Document Info

start page

  • 271

end page

  • 7

volume

  • 81

number

  • 3